ABC Breast Cancer Trials of Adjuvant Taxane With or Without Anthracycline in HER2-Negative Disease
In patients with high-risk HER2-negative breast cancer, taxane plus doxorubicin/cyclophosphamide (TaxAC) regimens improved invasive disease–free survival compared with docetaxel/cyclophosphamide (TC6) regimens. This result is based on an efficacy analysis of three adjuvant Anthracyclines in Early Breast Cancer (ABC) trials: U.S. Oncology Research (USOR) 06-090, National Surgical Adjuvant Breast and Bowel Project (NSABP) B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). These findings were reported in the Journal of Clinical Oncology by Blum and colleagues.
In these trials, with a median follow-up of 3.3 years, 2,125 patients randomly received TC6 regimens, and TaxAC regimens were randomly given to 2,117 patients. A total of 334 invasive disease–free survival events were reported, and the hazard ratio for TC6 vs TaxAC was 1.202 (95% confidence interval: 0.97–1.49), which signaled early reporting for futility. Furthermore, the 4-year invasive disease–free survival for those receiving TC6 regimens was 88.2%, vs 90.7% for those receiving TaxAC regimens (P=.04).
